Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Autotransplantation in solid tumors.

G Spitzer1

  • 1St. Louis University, Division of Medical Oncology, MO 63110-0250.

Blood Reviews
|June 1, 1991
PubMed
Summary
This summary is machine-generated.

High-dose therapy with autologous marrow support improves long-term survival for various cancers, including breast cancer and neuroblastoma. Further advancements in supportive care and treatment regimens show promise for overcoming resistant tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microcirculation in hypertensive patients.

Biorheology·2014
Same author

Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas.

Cancer journal (Sudbury, Mass.)·2009
Same author

Enhancing drug discovery through in silico screening: strategies to increase true positives retrieval rates.

Current medicinal chemistry·2008
Same author

Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer.

Clinical transplantation·2000
Same author

Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer.

JAMA·1999
Same author

Effects of allogeneic peripheral stem cell transplantation in a patient with job syndrome of hyperimmunoglobulinemia E and recurrent infections.

The American journal of medicine·1998
Same journal

Treating large B-cell lymphoma: Current strategies and unmet needs across community and academic settings.

Blood reviews·2026
Same journal

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026
Same journal

PRISMA-based systematic review on iron stores in repeat blood donors.

Blood reviews·2026
Same journal

Artificial intelligence applications in thrombotic thrombocytopenic Purpura: A systematic review of diagnostic, risk stratification, and prognostic models.

Blood reviews·2026
Same journal

Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group.

Blood reviews·2026
Same journal

The Lebanese national patient blood management guidelines: A new page in the medical practice.

Blood reviews·2026
See all related articles

Area of Science:

  • Oncology
  • Hematology
  • Cancer Therapeutics

Background:

  • Conventional therapies have limitations in achieving long-term remission for aggressive cancers.
  • Specific cancers like metastatic breast cancer, stage IV neuroblastoma, testicular cancer, and Ewing's sarcoma present significant treatment challenges.

Purpose of the Study:

  • To evaluate the efficacy of high-dose therapy with autologous marrow support in various advanced and recurrent cancers.
  • To compare outcomes of high-dose therapy against conventional treatment approaches.
  • To explore potential improvements for resistant tumors.

Main Methods:

  • Retrospective analysis of patient data from studies involving high-dose chemotherapy.
  • Administration of high-dose therapy followed by autologous marrow or stem cell support.

Related Experiment Videos

  • Comparison of survival rates and disease-free intervals with historical conventional therapy data.

    • Main Results:

    • High-dose therapy with autologous marrow support demonstrated an increased proportion of patients achieving long-term survival without evidence of disease.
    • Outcomes in subgroups treated with conventional therapy served as a benchmark for comparison.
    • The approach showed particular benefit in metastatic breast cancer, stage IV neuroblastoma, testicular cancer, and Ewing's sarcoma.

    Conclusions:

    • High-dose therapy with autologous marrow support is a viable strategy to improve long-term outcomes in select aggressive and recurrent cancers.
    • Advancements in supportive care and the development of non-cross-resistant regimens for recurrent high-dose therapy cycles hold potential for further enhancing patient outcomes.
    • These findings suggest broader applicability of high-dose therapy, potentially including more resistant tumor types.